Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Steven Isakoff, MD, PhD, Massachusetts General Hospital Identifier:
First received: October 30, 2008
Last updated: July 5, 2016
Last verified: July 2016
The purpose of this research study is to see if Near-Infrared Tomographic Optical Breast Imaging (TOBI) scans can help monitor breast tumor response during treatment for breast cancer. The images created by the TOBI scan show changes in blood blow and oxygen levels in breast tissue.

Condition Intervention
Breast Cancer
Device: Near-Infrared Tomographic Optical Breast Imaging

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Functional Metabolic Near-infrared Tomographic Optical Breast Imaging (TOBI) to Monitor Response to Neoadjuvant Therapy in Breast Cancer

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • To explore the feasibility of measuring optically derived parameters in the clinical setting. [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To explore the changes before and after neoadjuvant therapy of additional parameters derived from dynamic and static optical imaging of primary breast cancer. [ Time Frame: 4 years ] [ Designated as safety issue: No ]
  • To evaluate changes in optical imaging-derived deoxyhemoglobin concentration early in treatment in patients undergoing neoadjuvant therapy for breast cancer. [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 24
Study Start Date: August 2008
Estimated Study Completion Date: December 2016
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Optical Imaging
Tomographic Optical Imaging Arm
Device: Near-Infrared Tomographic Optical Breast Imaging
TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
Other Name: TOBI

Detailed Description:
  • Participants will have a TOBI scan prior to starting their cancer treatment and again on day 8 after their first treatment. Participants will also be asked if they would volunteer to undergoing one or more additional TOBI scans on days 2-7 after they begin cancer treatment. These additional scans are optional. Participants will also have a scan on the first day of each treatment cycle.
  • TOBI scans will be performed at the Gillette Center for Breast Cancer at the Massachusetts General Hospital.
  • For the scan, each breast is placed between 2 plastic plates in order to spread the tissue apart, similar to the procedure for a mammogram. The TOBI scanner is attached to these plates. We will apply mild pressure to compress the breast and the breast will be scanned using light waves. Each scan will take about 3 minutes.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult female patients presenting to the MGH Cancer Center Gillette Center for breast cancer neoadjuvant therapy
  • Subject who have had or will have a clinically indicated pre-treatment breast MRI

Exclusion Criteria:

  • Younger than 18 years of age
  • Open wounds on breast
  • Breast implants, because they may interfere with readings
  • Subjects who will be receiving preoperative therapy for <28 days
  • Breast surgery or biopsy < 10 days prior to optical imaging scan
  • Medical or psychiatric or other medical condition that the principal investigator believes may result in inability to complete the study
  • Bilateral breast cancers or a history of contralateral breast cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00783757

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Steven Isakoff, MD, PhD
Principal Investigator: Steven Isakoff, MD, PhD Massachusetts General Hospital
  More Information

Responsible Party: Steven Isakoff, MD, PhD, Attending Physician, Massachusetts General Hospital Identifier: NCT00783757     History of Changes
Other Study ID Numbers: 07-305 
Study First Received: October 30, 2008
Last Updated: July 5, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Massachusetts General Hospital:
neo-adjuvant chemotherapy
breast imaging
optical imaging

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on December 09, 2016